Synthesis and Mechanism of p53-MDM2 Inhibitors with Heterocyclic Structures: A Focused Review

被引:0
作者
Ji, Li-Tao [1 ]
Zhang, Wenjing [1 ]
Zhang, Yi [1 ]
Zhao, Su [1 ]
Long, Hai-Tao [1 ]
Qin, Li-Qing [1 ]
Tian, Jia-Cheng [1 ]
Li, Hong-Zhang [1 ]
Zhu, Dan-Xue [1 ]
Zhou, Yan [1 ]
Lu, Yi-Duo [1 ]
Wang, Zhen-Chao [1 ,2 ,3 ]
Li, Cheng-Peng [1 ,2 ,3 ]
机构
[1] Guizhou Univ, Coll Pharm, Guiyang 550025, Guizhou, Peoples R China
[2] Minist Educ, State Key Lab Breeding Base Green Pesticide & Agr, Key Lab Green Pesticide & Agr Bioengn, Guiyang 550025, Peoples R China
[3] Guizhou Univ, Guizhou Engn Lab Synthet Drugs, Guiyang 550025, Peoples R China
来源
CHEMISTRYSELECT | 2023年 / 8卷 / 45期
关键词
Small molecule; heterocyclic compounds; p53-MDM2; cancer; synthesis method; SMALL-MOLECULE INHIBITORS; PROTEIN-PROTEIN INTERACTION; STRUCTURE-BASED DESIGN; BIOLOGICAL EVALUATION; MDM2; INHIBITORS; SPIRO-OXINDOLES; CLINICAL-TRIALS; P53; PATHWAY; POTENT; DISCOVERY;
D O I
10.1002/slct.202302240
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
P53 gene mutation is one of the important causes in tumors. p53-MDM2 (murine double minute 2) inhibitors can interrupt p53-dependent gene transcription activity, and inhibit p53-mediated apoptosis, block p53-MDM2/MDMx interaction, and significantly reduce DNA formation. In this article, we focused on the synthesis methods about nutlins and other p53 small molecule inhibitors, in order to find potential new structure for novel p53 small molecule inhibitor synthesizing. Mutation of the p53 gene is among the most important causes of tumors. Inhibitors of p53-MDM2 can impede p53-dependent gene transcription, inhibit p53-mediated apoptosis, block p53-MDM2/MDMx interaction, and significantly reduce DNA formation. In this review we discuss the synthesis of nutlins and other small-molecule p53 inhibitors, with an aim to inspire new structures and methods for the synthesis of future small-molecule p53 inhibitors.+image
引用
收藏
页数:16
相关论文
共 50 条
  • [41] Discovery of 1-arylpyrrolidone derivatives as potent p53-MDM2 inhibitors based on molecule fusing strategy
    Li, Jin
    Wu, Yuelin
    Guo, Zizhao
    Zhuang, Chunlin
    Yao, Jianzhong
    Dong, Guoqiang
    Yu, Zhiliang
    Min, Xiao
    Wang, Shengzheng
    Liu, Yang
    Wu, Shanchao
    Zhu, Shiping
    Sheng, Chunquan
    Miao, Zhenyuan
    Zhang, Wannian
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (12) : 2648 - 2650
  • [42] Patented small molecule inhibitors of p53-MDM2 interaction
    Deng, JX
    Dayam, R
    Neamati, N
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2006, 16 (02) : 165 - 188
  • [43] Structure-activity relationship and antitumor activity of thio-benzodiazepines as p53-MDM2 protein-protein interaction inhibitors
    Guo, Zizhao
    Zhuang, Chunlin
    Zhu, Lingjian
    Zhang, Yongqiang
    Yao, Jianzhong
    Dong, Guoqiang
    Wang, Shengzheng
    Liu, Yang
    Chen, Hai
    Sheng, Chunquan
    Miao, Zhenyuan
    Zhang, Wannian
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2012, 56 : 10 - 16
  • [44] Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development
    Zhang, Zhuming
    Chu, Xin-Jie
    Liu, Jin-Jun
    Ding, Qingjie
    Zhang, Jing
    Bartkovitz, David
    Jiang, Nan
    Karnachi, Prabha
    So, Sung-Sau
    Tovar, Christian
    Filipovic, Zoran M.
    Higgins, Brian
    Glenn, Kelli
    Packman, Kathryn
    Vassilev, Lyubomir
    Graves, Bradford
    ACS MEDICINAL CHEMISTRY LETTERS, 2014, 5 (02): : 124 - 127
  • [45] Discovery of 1,2-Naphthoquinone Derivatives as Potent p53-MDM2 Interaction Inhibitors
    Jung, Myoung Eun
    Go, Areum
    Yoo, Dabin
    Chae, Jong-Hak
    Jeon, Moon-Kook
    Lim, Byungho
    Choi, Gildon
    BULLETIN OF THE KOREAN CHEMICAL SOCIETY, 2019, 40 (12) : 1236 - 1239
  • [46] FOLICation: Engineering approved drugs as potential p53-MDM2 interaction inhibitors for cancer therapy
    Patil, Sachin P.
    MEDICAL HYPOTHESES, 2013, 81 (06) : 1104 - 1107
  • [47] Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 2
    Wang, Weisi
    Lv, Dan
    Qiu, Ni
    Zhang, Lei
    Hu, Chunqi
    Hu, Yongzhou
    BIOORGANIC & MEDICINAL CHEMISTRY, 2013, 21 (11) : 2886 - 2894
  • [48] An update patent review of MDM2-p53 interaction inhibitors (2019-2023)
    Twarda-Clapa, Aleksandra
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2024, 34 (12) : 1177 - 1198
  • [49] Small molecule protein-protein inhibitors for the p53-MDM2 interaction
    Dudkina, Anna S.
    Lindsley, Craig W.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2007, 7 (10) : 952 - 960
  • [50] Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be Addressed
    Zanjirband, Maryam
    Rahgozar, Soheila
    CURRENT DRUG TARGETS, 2019, 20 (11) : 1091 - 1111